Spyre Therapeutics Inc
NASDAQ:SYRE

Watchlist Manager
Spyre Therapeutics Inc Logo
Spyre Therapeutics Inc
NASDAQ:SYRE
Watchlist
Price: 33.47 USD 1.24%
Market Cap: 2.6B USD

Operating Margin
Spyre Therapeutics Inc

0%
Current
-8 237%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-208.6m
/
Revenue
0

Operating Margin Across Competitors

No Stocks Found

Spyre Therapeutics Inc
Glance View

Market Cap
2.6B USD
Industry
Biotechnology

Spyre Therapeutics Inc. has positioned itself as a pioneering player in the biopharmaceutical landscape, carving a niche in the rapidly evolving field of gene therapy. Founded with a vision to tackle rare genetic disorders, the company harnesses cutting-edge CRISPR technology to develop precise therapies that can correct genetic mutations at their source. Spyre's business model is predicated on leveraging strategic partnerships with leading research institutions and utilizing its proprietary platforms to streamline the drug development process. By focusing on rare diseases, which often pose significant unmet medical needs, Spyre Therapeutics benefits from the advantages of orphan drug status, including market exclusivity, reducing regulatory hurdles, and commanding premium pricing for its innovative therapies. The company generates revenue primarily through licensing agreements, milestone payments, and royalties from its biotech collaborations. By out-licensing its proprietary technologies and therapeutic candidates, Spyre ensures a steady income stream to fuel its ambitious research and development endeavors. Moreover, its agile business approach allows it to pivot quickly, adapting to new scientific discoveries and market demands, which is critical in the dynamic biotech sector. Additionally, Spyre is exploring direct commercialization pathways for select therapies, eyeing the potential to capture a larger share of the revenue pie, though this comes with the challenge of scaling operations and building robust distribution channels. Overall, Spyre Therapeutics Inc. exemplifies modern resilience and innovation in the biotech industry, continuously finding ways to transform scientific potential into commercial success.

SYRE Intrinsic Value
6.27 USD
Overvaluation 81%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-208.6m
/
Revenue
0
What is the Operating Margin of Spyre Therapeutics Inc?

Based on Spyre Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top